Physician profile
Steven E Danziger
NPI 1588187231
$9,248.20
in general payments reported to CMS, 2019-2025
44 companies · $2,921 in 2025
The $2,921 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $181 · 2023: $2,785 · 2024: $3,361 · 2025: $2,921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,058 · Travel and Lodging: $8.91 · Education: $0.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,057.77 |
| Travel and Lodging | $8.91 |
| Education | $0.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,441.55 | 2023-2025 | Austedo Xr, Austedo, Austedo Xr |
| Sk Life Science, INC. | $1,000.81 | 2022-2025 | Xcopri |
| Abbvie INC. | $807.13 | 2022-2025 | Botox, Ubrelvy, Duopa |
| Avadel Cns Pharmaceuticals, LLC | $761.79 | 2023-2025 | Lumryz |
| Pfizer INC. | $600.34 | 2023-2025 | |
| Lilly USA, LLC | $418.13 | 2022-2025 | Emgality, Reyvow, Amyvid |
| Lundbeck LLC | $390.92 | 2022-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $322.94 | 2024-2025 | |
| Celgene Corporation | $281.42 | 2022-2025 | Zeposia |
| Argenx US, INC. | $266.98 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Ucb, INC. | $265.07 | 2022-2025 | Briviact, Nayzilam, Rystiggo |
| Neurocrine Biosciences, INC. | $258.83 | 2023-2025 | Ingrezza, Ongentys |
| Eisai INC. | $236.11 | 2024-2025 | |
| Kyowa Kirin, INC. | $216.58 | 2023-2025 | Nourianz |
| Csl Behring | $179.47 | 2022-2025 | Hizentra |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $148.62 | 2023-2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $146.82 | 2022-2025 | Ultomiris |
| Neurelis, INC. | $145.35 | 2023-2025 | Valtoco |
| Genentech USA, INC. | $95.33 | 2022-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Jazz Pharmaceuticals INC. | $95.00 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $91.56 | 2023-2025 | Onpattro, Amvuttra |
| Astrazeneca Pharmaceuticals LP | $90.64 | 2023-2025 | Wainua |
| Ipsen Biopharmaceuticals, INC | $87.68 | 2024-2025 | Dysport |
| Otsuka America Pharmaceutical, INC. | $87.49 | 2024-2025 | Rexulti |
| Aucta Pharmaceuticals, INC. | $82.56 | 2024-2025 | Motpoly Xr |
| Axsome Therapeutics, INC. | $74.83 | 2025 | Symbravo |
| Merz Pharmaceuticals, LLC | $68.98 | 2025 | Xeomin, Inbrija |
| Azurity Pharmaceuticals, INC. | $68.39 | 2023-2024 | Horizant, Horizant |
| Biogen, INC. | $64.79 | 2023-2024 | Vumerity, Tysabri, Avonex |
| Harmony Biosciences LLC | $60.76 | 2023-2025 | Wakix |
| Tg Therapeutics, INC. | $52.66 | 2025 | |
| Medtronic, INC. | $52.65 | 2025 | Minimed 780g |
| Scilex Pharmaceuticals INC. | $48.71 | 2024 | |
| Ge Healthcare | $44.59 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $32.78 | 2023 | Belsomra, Verquvo, Steglatro |
| Neuronetics, INC. | $26.18 | 2024 | Neurostar Tms Therapy System |
| Janssen Biotech, INC. | $18.42 | 2025 | |
| Vanda Pharmaceuticals INC. | $18.36 | 2025 | Ponvory |
| Insightec,INC | $16.89 | 2025 | Exablate |
| Life Molecular Imaging LTD | $16.87 | 2024 | Neuraceq |
| Corium, LLC | $16.66 | 2023 | Azstarys |
| Acorda Therapeutics, INC | $16.05 | 2024 | Inbrija |
| Xeris Pharmaceuticals, INC. | $15.49 | 2023 | Gvoke Hypopen |
| Almatica Pharma LLC | $15.02 | 2023 | Gralise |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Danziger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.